ProMIS Neurosciences, Inc. (PMN)
11.27
-0.30
(-2.59%)
USD |
NASDAQ |
Sep 25, 16:00
11.49
+0.22
(+1.95%)
After-Hours: 19:59
ProMIS Neurosciences Enterprise Value : 47.60M for Sept. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 25, 2026 | 47.60M |
| September 24, 2026 | 50.29M |
| September 23, 2026 | 62.58M |
| September 22, 2026 | 68.32M |
| September 21, 2026 | 68.77M |
| September 18, 2026 | 72.17M |
| September 17, 2026 | 67.24M |
| September 16, 2026 | 62.04M |
| September 15, 2026 | 62.13M |
| September 14, 2026 | 65.45M |
| September 11, 2026 | 68.14M |
| September 10, 2026 | 66.70M |
| September 09, 2026 | 75.36M |
| September 08, 2026 | 58.90M |
| September 04, 2026 | 59.53M |
| September 03, 2026 | 62.22M |
| September 02, 2026 | 71.86M |
| September 01, 2026 | 66.26M |
| August 31, 2026 | 63.74M |
| August 28, 2026 | 70.16M |
| August 27, 2026 | 72.00M |
| August 26, 2026 | 76.21M |
| August 25, 2026 | 84.28M |
| August 24, 2026 | 79.26M |
| August 21, 2026 | 76.66M |
| Date | Value |
|---|---|
| August 20, 2026 | 80.25M |
| August 19, 2026 | 78.00M |
| August 18, 2026 | 80.87M |
| August 17, 2026 | 78.00M |
| August 14, 2026 | 79.80M |
| August 13, 2026 | 79.17M |
| August 12, 2026 | 76.57M |
| August 11, 2026 | 80.78M |
| August 10, 2026 | 78.54M |
| August 07, 2026 | 78.45M |
| August 06, 2026 | 66.08M |
| August 05, 2026 | 67.42M |
| August 04, 2026 | 68.23M |
| August 03, 2026 | 73.34M |
| July 31, 2026 | 69.57M |
| July 30, 2026 | 80.34M |
| July 29, 2026 | 72.62M |
| July 28, 2026 | 76.75M |
| July 27, 2026 | 51.64M |
| July 24, 2026 | 55.94M |
| July 23, 2026 | 59.62M |
| July 22, 2026 | 72.00M |
| July 21, 2026 | 76.48M |
| July 20, 2026 | 81.73M |
| July 17, 2026 | 82.76M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Edesa Biotech, Inc. | 36.71M |
| Arrowhead Pharmaceuticals, Inc. | 9.078B |
| Oncolytics Biotech, Inc. | 81.50M |
| Sangamo Therapeutics, Inc. | 51.40M |
| Sarepta Therapeutics, Inc. | 2.229B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -11.73M |
| Total Expenses (Quarterly) | 11.73M |
| EPS Diluted (Quarterly) | -1.283 |
| Earnings Yield | -119.2% |
| Normalized Earnings Yield | -119.21 |